Literature DB >> 19184652

Molecular genetics of nicotine metabolism.

Jill C Mwenifumbo1, Rachel F Tyndale.   

Abstract

The molecular genetics of nicotine metabolism involves multiple polymorphic catalytic enzymes. Variation in metabolic pathways results in nicotine disposition kinetics that differ between individuals and ethnic groups. Twin studies indicate that a large part of this variance is genetic in origin, although environmental influences also contribute. The primary aim of this chapter is to review the current knowledge regarding the genetic variability in the enzymes that metabolize nicotine in humans. The focus is on describing the genetic polymorphisms that exist in cytochromes P450 (CYPs), aldehyde oxidase 1 (AOX1), UDP-glucuronosyltransferases (UGTs), and flavin-containing monooxygenase 3 (FMO3). Genetic studies have demonstrated that polymorphisms in CYP2A6, the primary enzyme responsible for nicotine breakdown, make a sizable contribution to the wide range of nicotine metabolic capacity observed in humans. Thus, special attention will be given to CYP2A6, because slower nicotine metabolism requires less frequent self-administration, and accordingly influences smoking behaviors. In addition, the molecular genetics of nicotine metabolism in nonhuman primates, mice, and rats will be reviewed briefly.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19184652     DOI: 10.1007/978-3-540-69248-5_9

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  30 in total

1.  Simultaneous quantification of nicotine and metabolites in rat brain by liquid chromatography-tandem mass spectrometry.

Authors:  Paula L Vieira-Brock; Eleanor I Miller; Shannon M Nielsen; Annette E Fleckenstein; Diana G Wilkins
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-09-18       Impact factor: 3.205

2.  Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation.

Authors:  Evan T Ogburn; David R Jones; Andrea R Masters; Cong Xu; Yingying Guo; Zeruesenay Desta
Journal:  Drug Metab Dispos       Date:  2010-03-24       Impact factor: 3.922

3.  Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy.

Authors:  C Lerman; C Jepson; E P Wileyto; F Patterson; R Schnoll; M Mroziewicz; N Benowitz; R F Tyndale
Journal:  Clin Pharmacol Ther       Date:  2010-03-24       Impact factor: 6.875

4.  Dose-independent kinetics with low level exposure to nicotine and cotinine.

Authors:  Neal L Benowitz; Delia Dempsey; Rachel F Tyndale; Gideon St Helen; Peyton Jacob
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

5.  APOE e4 genotype and cigarette smoking in adults with normal cognition and mild cognitive impairment: a retrospective baseline analysis of a national dataset.

Authors:  Raj K Kalapatapu; Kevin L Delucchi
Journal:  Am J Drug Alcohol Abuse       Date:  2013-06-28       Impact factor: 3.829

6.  Personalized medicine and tobacco-related health disparities: is there a role for genetics?

Authors:  Chris Carlsten; Abigail Halperin; Julia Crouch; Wylie Burke
Journal:  Ann Fam Med       Date:  2011 Jul-Aug       Impact factor: 5.166

7.  A compensatory effect upon splicing results in normal function of the CYP2A6*14 allele.

Authors:  A Joseph Bloom; Oscar Harari; Maribel Martinez; Xiaochun Zhang; Sandra A McDonald; Sharon E Murphy; Alison Goate
Journal:  Pharmacogenet Genomics       Date:  2013-03       Impact factor: 2.089

Review 8.  Pharmacogenetics of nicotine addiction: role of dopamine.

Authors:  Aryeh I Herman; Elise E DeVito; Kevin P Jensen; Mehmet Sofuoglu
Journal:  Pharmacogenomics       Date:  2014-02       Impact factor: 2.533

9.  Associations of cytochrome P450 oxidoreductase genetic polymorphisms with smoking cessation in a Chinese population.

Authors:  Huijie Li; Suyun Li; Qiang Wang; Chongqi Jia
Journal:  Hum Genet       Date:  2016-09-22       Impact factor: 4.132

Review 10.  Precision medicine and pharmacogenetics: what does oncology have that addiction medicine does not?

Authors:  Henry R Kranzler; Rachel V Smith; Robert Schnoll; Afaf Moustafa; Emma Greenstreet-Akman
Journal:  Addiction       Date:  2017-04-21       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.